Home › Overactive Bladder › NCT06797245
APPROVE Trial: Evaluating a Prescription Digital Therapeutic for Treatment of OAB in Women
The APPROVE Trial: A Randomized Controlled Trial Evaluating the Efficacy and Safety of a Prescription Digital Therapeutic for Treatment of Overactive Bladder in Women
Who can join
Ages 22 and older · Women
Full eligibility criteria
Inclusion Criteria: * Women ≥ 22 years old * Bothersome OAB symptoms (defined as bother rating ≥ 5 on ICIQ-FLUTS question #3b or #9b) * English-speaking * Willing to forego other treatment outside of medications for the 8-week trial period * Use of at least one mobile App Exclusion Criteria: * Stress-predominant mixed urinary incontinence (defined as QUID stress score \> QUID urge score) * Voiding dysfunction defined as response ≥ 2 on ICIQ-FLUTS question #7a * Bladder pain defined as response ≥ 2 on ICIQ-FLUTS question #4a * Use of an OAB medication (anticholinergic or beta-agonist) within the past two weeks * Currently using intermittent or indwelling catheter * History of bladder/urethral, colon/anal, or cervical cancer * Current or prior use of sacral neuromodulation, tibial stimulation or onabotulinum toxin type A intradetrusor injection * Currently taking antibiotics/drugs for urinary tract infection\^ * Currently undergoing or unwilling to forego pelvic floor physical therapy with a physical therapist or prescription device for the 8-week intervention period * Planning surgery for pelvic organ prolapse within 12 months of randomization * Pelvic surgery within the past 6 months * Planning to undergo pessary fitting ° * Those on antibiotics for urinary tract infection will be eligible for enrollment 2 weeks after completing antibiotic therapy with subjective resolution of UTI symptoms °Will be eligible after completing pessary fitting https://researchdata.medstar.net/redcap/surveys/?s=MM7WN7EXACX4PNXJ
About the study
The APPROVE trial is a multi-centered, randomized controlled trial designed to assess differences in symptom improvement, quality of life, bladder symptoms, satisfaction with treatment and continued treatment efficacy in women with overactive bladder (OAB) randomized to a prescription digital therapeutic (PDTx) app called RiSolve compared to standard behavioral education (handouts).
What is being tested
- RiSolve App (device)
- AUGS Patient Handouts (behavioral)
Sponsor: Medstar Health Research Institute · Participants: 596 · Started: Mar 17, 2025
Contact the study team
- Patricia Moriarty · Phone: 202-877-0486
- Alexis Dieter, MD · Phone: 202-877-6526
Official record on ClinicalTrials.gov — NCT06797245
Locations in the U.S.
| Alabama | University of Alabama at Birmingham, Birmingham |
| California | Stanford University, Palo Alto |
| District of Columbia | MedStar Health, Washington D.C. |
| Illinois | University of Chicago, Chicago |
| North Carolina | Atrium Health Wake Forest Baptist, Winston-Salem |
| Pennsylvania | Allegheny Health, Pittsburgh |
| South Carolina | Medical University of South Carolina Health, Charleston |
| Texas | UT Southwestern Medical Center, Dallas |
| Wisconsin | University of Wisconsin, Madison |
Conditions
From ClinicalTrials.gov, data retrieved Sep 29, 2026. Each study sets its own eligibility; the study team decides who can join.